No headlines found.
Globe Newswire (Mon, 2-Mar 8:00 AM ET)
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Monopar Therapeutics trades on the NASDAQ stock market under the symbol MNPR.
As of March 19, 2026, MNPR stock price climbed to $58.67 with 192,396 million shares trading.
MNPR has a beta of 1.51, meaning it tends to be more sensitive to market movements. MNPR has a correlation of 0.08 to the broad based SPY ETF.
MNPR has a market cap of $392.07 million. This is considered a Small Cap stock.
In the last 3 years, MNPR traded as high as $105.00 and as low as $1.37.
The top ETF exchange traded funds that MNPR belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
MNPR has outperformed the market in the last year with a price return of +70.7% while the SPY ETF gained +18.9%. However, in the short term, MNPR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -11.1% vs -1.9% return in SPY. But in the last 2 weeks, MNPR shares have fared better than the market returning +5.7% compared to SPY -3.7%.
MNPR support price is $56.00 and resistance is $60.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNPR shares will trade within this expected range on the day.
